Provided by Tiger Fintech (Singapore) Pte. Ltd.

Guardant Health Inc.

42.66
+1.182.84%
Post-market: 43.140.4800+1.13%19:06 EST
Volume:1.69M
Turnover:71.04M
Market Cap:5.27B
PE:-12.00
High:42.97
Open:41.01
Low:40.59
Close:41.48
Loading ...

Morgan Stanley Adjusts Price Target on Guardant Health to $52 From $42, Keeps Overweight Rating

MT Newswires Live
·
11 hours ago

Guardant Health Joins Forces With Dak Prescott’s Faith Fight Finish Foundation and Feist-Weiller Cancer Center’s Partners in Wellness to Boost Colon Cancer Screening in Underserved Communities

Business Wire
·
Yesterday

GH Research’s Promising Growth Potential: Buy Rating Backed by Strong Clinical Data and Financial Position

TIPRANKS
·
04 Mar

Guardant Health’s (NASDAQ:GH) Q4: Beats On Revenue

StockStory
·
04 Mar

Why GH Research PLC (GHRS) is Skyrocketing So Far in 2025

Insider Monkey
·
04 Mar

GH Research PLC (GHRS): Among the Best Psychedelic Stocks to Buy in 2025

Insider Monkey
·
02 Mar

Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
01 Mar

Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire
·
01 Mar

Promising Trial Results and Strong Financials Justify Buy Rating for GH Research

TIPRANKS
·
28 Feb

Analysts Are Bullish on Top Healthcare Stocks: GH Research (GHRS), Cullinan Management (CGEM)

TIPRANKS
·
28 Feb

Psychedelic: GH Research, Compass Pathways report earnings results

TIPRANKS
·
28 Feb

GH Research Is Maintained at Buy by Stifel

Dow Jones
·
27 Feb

New Guardant Health/Harris Poll Survey Highlights Patient Fear and Anxiety as Major Barriers to Colorectal Cancer Screening, but Blood Test Option Offers Hope for Change

Business Wire
·
27 Feb

GH Research 2024 GAAP EPS $(0.75), Down From $(0.68) YoY

Benzinga
·
27 Feb

GH Research Reports Full Year 2024 Financial Results and Provides Business Updates

GlobeNewswire
·
27 Feb

Guardant Health Is Maintained at Overweight by Piper Sandler

Dow Jones
·
27 Feb